To Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effects of IMM-H014 in Healthy Subjects
Phase 1
Recruiting
- Conditions
- Nonalcoholic Steatohepatitis (NASH)
- Interventions
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Changchun Intellicrown Pharmaceutical Co. LTD
- Target Recruit Count
- 138
- Registration Number
- NCT06216041
- Locations
- 🇨🇳
The first Bethune hospital of Jilin University, Changchun, Jilin, China
ZZ06 in Adult Patients With Advanced EGFR Positive Solid Tumor Malignancies
Phase 1
- Conditions
- Advanced EGFR Positive Solid Tumor
- Interventions
- Biological: ZZ06
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Changchun Intellicrown Pharmaceutical Co. LTD
- Target Recruit Count
- 60
- Registration Number
- NCT04412616
- Locations
- 🇺🇸
Kansas University Cancer Center, Fairway, Kansas, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
🇨🇳Jilin Cancer Hospital, Changchun, Jilin, China
Phase I Study of KN044 in Locally Advanced/Metastatic Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- Biological: KN044
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Changchun Intellicrown Pharmaceutical Co. LTD
- Target Recruit Count
- 39
- Registration Number
- NCT04126590
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath